Seattle Genetics (SGEN) Tops Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Seattle Genetics (SGEN) PT Cut at BofA/Merrill Lynch on Lower Adcetris Sales
February 11, 2015 6:57 AM ESTBofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating while lowering estimates and his price target on Seattle Genetics (NASDAQ: SGEN) to $33.00 (from $35.00) on cautious Adcetris sales.
Byrne notes Adcetris guidance represents around 15% year-over-year growth. Meanwhile, the analyst sees 2015 U.S.... More
